Advancing Early Detection in Liver Cancer to Save Lives
Saving Lives through early detection of liver cancer through their propetry test Episcreen Liver.
About Tvaster Genkalp
Tvaster Genkalp is a pioneering healthtech company focused on innovating liver cancer diagnostics through its proprietary liquid biopsy platform. Their flagship product, Episcreen Liver, is a hypermethylation-based diagnostic test for early and accurate detection of Hepatocellular Carcinoma (HCC), the most common form of liver cancer.
Breakthrough Technology: Tvaster’s liquid biopsy detects liver cancer through epigenetic hypermethylation markers, offering a more accurate and stable alternative to traditional genetic mutation-based assays.
Clinical Performance: Tested over 600 patients, Episcreen Liver has demonstrated 91% sensitivity and 88% specificity with high detection rates across all stage.
Full Diagnostic Suite: In addition to HCC, Tvaster has also developed diagnostics for bile cancer and pediatric liver cancer.
Clinical Applications: The technology not only supports early detection but also supports recurrence monitoring post treatment and potential use as a companion diagnostic for pharma partners in liver cancer therapeutics.
Meet the Founders:
Fund II
BioTech
Where We Fuel Innovation and Sustainable Growth
We partner with visionary founders across these industries, bridging bold ideas with resources for real-world impact and lasting change.
Stay Inspired with Our Latest Articles
Explore insights and stories that fuel startup innovation through our curated articles and expert perspectives.
Ten Years In: Backing Deep Tech Before It Was a Wave
Why did we Invest - Tvaster Genkalp
Why did we invest? — BluJ Aero
Ready to Build the Future Together?
Let’s turn your bold ideas into transformative realities. with Ideaspring Capital to scale innovation, accelerate growth, and make a lasting impact in the world of technology.
